Appointment as Nominated Advisor and Broker to TheraCryf plc

Home Appointment as Nominated Advisor and Broker to TheraCryf plc

June 2025 - Deal Announcements

Singer Capital Markets is delighted to have been appointed as Nominated Advisor and Broker to TheraCryf plc with immediate effect.

About TheraCryf plc

TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma.

Ticker: TCF
Market Cap: £5.5 million*
Website: Click here

*As of 12^th June 2025

Account Team

Investment Banking
Phil Davies Managing Director, Investment Banking Email \| Call	Ollie Platts Assistant Director, Investment Banking Email \| Call	Patrick Weaver Analyst, Investment Banking Email \| Call

Investment Banking

Phil Davies
Managing Director,

Investment Banking
Email | Call

Ollie Platts
Assistant Director,

Investment Banking
Email | Call

Patrick Weaver
Analyst,

Investment Banking
Email | Call

Research and Sales
Karl Keegan Head of Research Email \| Call	Jonathan Dighe Equity Sales Email \| Call

Investor Relations
Emily Conroy Investor Relations Email \| Call